Enzyme inhibition, radical scavenging, and spectroscopic studies of vanadium(IV)–hydrazide complexes
暂无分享,去创建一个
U. Ashiq | M. Mahroof-Tahir | M. Choudhary | K. Khan | Z. Maqsood | R. A. Jamal | Iman Omer | R. Jamal
[1] R. Vijayaraghavan,et al. New diketone based vanadium complexes as insulin mimetics. , 2008, European journal of medicinal chemistry.
[2] S. S. Soares,et al. Vanadium and cadmium in vivo effects in teleost cardiac muscle: metal accumulation and oxidative stress markers. , 2008, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.
[3] Yan-fen Niu,et al. Effects of bis(α-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats , 2007 .
[4] C. Suresh,et al. Rapid reduction and complexation of vanadium by 1-phenyl-3-methyl-4-toluoyl-5-pyrazolone: Spectroscopic characterization and structure modelling , 2007 .
[5] Zheng Sun,et al. Insulin-like model complexes: Synthesis, spectra characterization and crystal structure of two novel oxovanadium complexes with poly(pyrazolyl)borate ligands VO(HB(pz)3)(H2B(pz)2) and VO(B(pz)4)2 , 2007 .
[6] S. Feng,et al. Dinuclear oxovanadium(IV) compounds from designed amino acid derivatives , 2007 .
[7] U. Ashiq,et al. Chemistry, Urease Inhibition, and Phytotoxic Studies of Binuclear Vanadium(IV) Complexes , 2007, Chemistry & biodiversity.
[8] Y. Adachi,et al. Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes. , 2006, Life sciences.
[9] C. Supuran,et al. Oxovanadium(IV) complexes of hydrazides: Potential antifungal agents , 2006, Journal of enzyme inhibition and medicinal chemistry.
[10] M. Drew,et al. Synthesis, structure and solution chemistry of mixed-ligand oxovanadium(IV) and oxovanadium(V) complexes incorporating tridentate ONO donor hydrazone ligands , 2005 .
[11] I. Sóvágó,et al. Vanadium(III) binding strengths of small biomolecules , 2005 .
[12] Thomas J. Meyer,et al. Comprehensive Coordination Chemistry II , 2004 .
[13] S. Chakraborty,et al. X-ray, spectral and biological (antimicrobial and superoxide dismutase) studies of oxalato bridged CuII-NiII and CuII-ZnII complexes with pentamethyldiethylenetriamine as capping ligand. , 2004, Journal of inorganic biochemistry.
[14] D. Crans,et al. The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds. , 2004, Chemical reviews.
[15] T. Ueki,et al. Vanadium-binding protein in a vanadium-rich ascidian Ascidia sydneiensissamea: CW and pulsed EPR studies. , 2003, Journal of the American Chemical Society.
[16] B. Suresh,et al. Antioxidant activity of the ethanolic extract of Striga orobanchioides. , 2003, Journal of ethnopharmacology.
[17] D. Rehder,et al. Thiofunctional vanadium complexes. , 2002, Inorganic chemistry.
[18] Hiromu Sakurai,et al. Antidiabetic vanadium(IV) and zinc(II) complexes , 2002 .
[19] K. A. Salib,et al. METAL COMPLEXES OF NOVEL SYMMETRICAL SCHIFF BASE LIGANDS , 2001 .
[20] P. Schauerte,et al. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. , 2001, The American journal of pathology.
[21] A. Ceriello. Oxidative stress and glycemic regulation. , 2000, Metabolism: clinical and experimental.
[22] Y. Glories,et al. Free radical scavenging effect of anthocyanins in red wines , 1999 .
[23] J. McNeill,et al. Vanadium Complexes as Insulin Mimetic Agents: Coordination Chemistry and in Vivo Studies of Oxovanadium(IV) and Dioxovanadate(V) Complexes Formed from Naturally Occurring Chelating Oxazolinate, Thiazolinate, or Picolinate Units† , 1999 .
[24] Meir Shinitzky,et al. Enhancement and inhibition of snake venom phosphodiesterase activity by lysophospholipids , 1998, FEBS letters.
[25] M. Ávalos,et al. Glycine‐enhanced inhibition of rat liver nucleotide pyrophosphatase/phosphodiesterase‐I by EDTA: a full account of the reported inhibition by commercial preparations of acidic fibroblast growth factor (FGF‐1) , 1998, FEBS letters.
[26] L. Pettersson,et al. Speciation in vanadium bioinorganic systems , 1997 .
[27] D. D. Mishra,et al. Oxovanadium binuclear (IV) Schiff base complexes derived from aroyl hydrazones having subnormal magnetic moments , 1997 .
[28] E. Tiekink,et al. MONO- AND DINUCLEAR OXOVANADIUM(IV) COMPOUNDS CONTAINING VO(ONS) BASIC CORE : SYNTHESIS, STRUCTURE AND SPECTROSCOPIC PROPERTIES , 1997 .
[29] C. Orvig,et al. Oxidation Kinetics of the Potent Insulin Mimetic Agent Bis(maltolato)oxovanadium(IV) (BMOV) in Water and in Methanol. , 1996, Inorganic chemistry.
[30] C. R. Cornman,et al. Vanadium(IV) Complexes of an Active-Site Peptide of a Protein Tyrosine Phosphatase , 1995 .
[31] L. Pettersson,et al. Speciation in Vanadium Bioinorganic Systems. 2. An NMR, ESR, and Potentiometric Study of the Aqueous H(+)-Vanadate-Maltol System. , 1995, Inorganic chemistry.
[32] Keiichiro Suzuki,et al. Apoptotic Cell Death Triggered by Nitric Oxide in Pancreatic β-Cells , 1995, Diabetes.
[33] Ikezawa Hiroh,et al. Alkaline phosphodiesterase I release from eucaryotic plasma membranes by phosphatidylinositol-specific phospholipase C--IV. The release from Cacia porcellus organs. , 1994 .
[34] M. Deutscher. Ribonuclease multiplicity, diversity, and complexity. , 1993, The Journal of biological chemistry.
[35] Xuefeng Yin,et al. Vanadium as a modulator of cellular regulatory cascades and oncogene expression. , 1993, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[36] N. Takasu,et al. Streptozocin- and Alloxan-Induced H2O2 Generation and DNA Fragmentation in Pancreatic Islets: H2O2 as Mediator for DNA Fragmentation , 1991, Diabetes.
[37] A. Kanthasamy,et al. Antioxidant effect of vanadate on experimental diabetic rats , 1990, Acta diabetologia latina.
[38] Arthur I. Vogel,et al. Vogel's Textbook of Quantitative Chemical Analysis , 1989 .
[39] M. Deutscher. The metabolic role of RNases. , 1988, Trends in biochemical sciences.
[40] S P Wolff,et al. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. , 1987, The Biochemical journal.
[41] M. Buse,et al. The Inhibition of Islet Superoxide Dismutase by Diabetogenic Drugs , 1981, Diabetes.
[42] W. Geary. The use of conductivity measurements in organic solvents for the characterisation of coordination compounds , 1971 .
[43] A. Mclean,et al. Biochemical mechanisms of liver injury. , 1970, The American journal of medicine.
[44] H. G. Khorana,et al. Studies on polynucleotides , 1965 .
[45] W. E. Razzell,et al. Studies on polynucleotides. III. Enzymic degradation; substrate specificity and properties of snake venom phosphodiesterase. , 1959, The Journal of biological chemistry.
[46] D. Rehder. Bioinorganic Vanadium Chemistry , 2008 .
[47] H. Kaneto,et al. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. , 1995, Diabetes.
[48] H. Ikezawa,et al. Alkaline phosphodiesterase I release from eucaryotic plasma membranes by phosphatidylinositol-specific phospholipase C--IV. The release from Cacia porcellus organs. , 1994, The International journal of biochemistry.
[49] W. Linert,et al. SPECTROSCOPIC, ELECTROCHEMICAL AND QUANTUM MECHANICAL INVESTIGATIONS OF VANADYL(IV)-ACETYLACETONATE IN NON-AQUEOUS SOLUTIONS , 1993 .
[50] Sprinkle Tj. 2',3'-cyclic nucleotide 3'-phosphodiesterase, an oligodendrocyte-Schwann cell and myelin-associated enzyme of the nervous system. , 1989, Critical reviews in neurobiology.